Promising role of long non-coding RNA PCAT6 in malignancies

Long non-coding RNAs (lncRNAs), a newly identified class of non-coding RNA (ncRNA), are defined as RNA molecules at least 200 nucleotides in length that are not translated into proteins. LncRNAs contribute to a wide range of biological processes and are master regulators of disease occurrence, development, and response to therapy in human malignancies. The lncRNA prostate cancer-associated transcript 6 (PCAT6) is upregulated in various human malignancies, including lung cancer, hepatocellular carcinoma, cervical cancer, osteosarcoma, glioblastoma, colorectal cancer, breast cancer, gastric cancer, gastrointestinal stromal tumors, and pancreatic ductal adenocarcinoma. High expression of PCAT6 is closely correlated with aggressive clinicopathological characteristics and poor prognosis in cancer patients, suggesting it is an oncogenic lncRNA. PCAT6 over expression also facilitates cell proliferation, invasion, and migration while attenuating apoptosis, indicating that it might serve as a new prognostic biomarker and therapeutic target for malignancies. Here, we discuss the molecular mechanisms, regulatory functions, and potential clinical applications of PCAT6 in cancer.

Automated summary

Long non-coding RNAs (lncRNAs) are a newly identified class of RNA molecules at least 200 nucleotides in length that are not translated into proteins. The lncRNA prostate cancer-associated transcript 6 (PCAT6) is upregulated in various human malignancies and is closely correlated with aggressive clinicopathological characteristics and poor prognosis in cancer patients, indicating it is an oncogenic lncRNA that could serve as a new prognostic biomarker and therapeutic target for malignancies. The molecular mechanisms, regulatory functions, and potential clinical applications of PCAT6 in cancer are discussed.